A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy,
Safety, Tolerability and Pharmacokinetics of SNS812 in Participants with Mild to Moderate
COVID-19